Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25185296 | 1.00 | DPP4 (0.49) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL30543781 | 1.00 | DPP4 (0.49) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL25185297 | 1.00 | DPP4 (0.49) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL25471781 | 0.93 | DPP4 (0.48) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL29257790 | 0.93 | DPP4 (0.48) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL30969460 | 0.93 | DPP4 (0.48) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL29257794 | 0.93 | DPP4 (0.48) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL30543841 | 0.89 | DPP4 (0.45) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL25339963 | 0.89 | DPP4 (0.45) | DPP4GPR119MMP13IDO1TDO2 | |
| SCHEMBL31598989 | 0.88 | TACR1 (0.48) | DPP4GPR119MMP13IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-06-05 | — | — | US | disclosed |
| WO-2025103442-A1 | SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-20250042847-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-118055927-A | Substituted phenylpropionic acid derivative and application thereof | 上海拓界生物医药科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023078333-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078333-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042847-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | SLC5A2, PAH, TGFB2 | DPP4 35/4885GPR119 265/4885MMP13 2433/4885 |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | PCSK9, LPL, LYPLA1 | DPP4 125/4885GPR119 474/4885MMP13 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.